NovaBridge Biosciences (NBP) intrinsic value & 10-year financials
NovaBridge Biosciences (NBP) has a Graham intrinsic value of CNY 99.65 per share.
- Graham intrinsic value
- CNY 99.65
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 15.7%
- ROIC (10-yr avg)
- 4.1%
- Free cash flow (FY2025)
- —
NBP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -CNY 88.3M | — | — | — | — |
| FY2024 | — | -CNY 22.2M | — | — | — | -1.5% |
| FY2023 | CNY 27.6M | -CNY 1.5B | -CNY 7.66 | -CNY 1.3B | -260.5% | -74.8% |
| FY2022 | -CNY 221.6M | -CNY 2.5B | -CNY 13.21 | -CNY 1.1B | 24.0% | -1.6% |
| FY2021 | CNY 88.0M | -CNY 2.3B | -CNY 13.35 | -CNY 1.0B | — | -52.3% |
| FY2020 | CNY 1.5B | CNY 470.9M | CNY 3.00 | CNY 425.6M | — | 34.2% |
| FY2019 | CNY 30.0M | -CNY 1.5B | -CNY 9.58 | -CNY 880.2M | — | 89.0% |
| FY2018 | CNY 53.8M | -CNY 402.8M | -CNY 2.94 | -CNY 295.1M | — | 36.1% |
| FY2017 | CNY 11.6M | -CNY 298.2M | -CNY 2.47 | -CNY 272.5M | — | — |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in CNY.
Executive summary
NovaBridge Biosciences revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
NovaBridge Biosciences has historically struggled to out-earn its cost of capital, averaging just 4.1% ROIC.
NovaBridge Biosciences capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, NovaBridge Biosciences is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $99.65 per share.